102 results
Page 3 of 6
PRE 14A
55y gktqflncja8
7 Apr 23
Preliminary proxy
4:02pm
8-K
EX-99.2
j3m2sr6my9qz53oxlpkv
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
EX-99.1
op2a3n
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
vkmf omkfx
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
8-K
EX-1.1
rbs35
20 May 22
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
ide180l
6 May 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.2
nara0 8e7r0pgh
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.3
c4n9k021hdx92
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
2t7wwofniv c8h5ff
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
EX-99.1
1gce33x7ofhd0ogbk8
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.2
wt8iqm dyx
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.1
ii82ar4bcz
9 Sep 21
Regulation FD Disclosure
7:00am